Biotechnology News and Research

RSS

Aquatrove Biosciences announces positive results from Conceive Plus study

Aquatrove Biosciences, Inc. presented positive results from a study demonstrating that the technology used in Conceive Plus™ may assist trying to conceive couples. These data were recently presented at the 65th Annual Meeting of the American Society for Reproductive Medicine (ASRM).

27 Oct 2009

Alkermes commences ALKS 37 phase 1 clinical trial for the treatment of opioid-induced constipation

Alkermes, Inc. today announced the initiation of a phase 1 clinical study of ALKS 37, an orally active, peripherally-restricted opioid antagonist with potential to block the opioid agonist effects on gastrointestinal motility, commonly referred to as opioid-induced constipation (OIC). The randomized, double-blind, placebo-controlled study will assess the safety, tolerability and pharmacokinetic effects of a single oral administration of five doses of ALKS 37 in approximately 40 healthy volunteers.

27 Oct 2009

ImmunoCellular Therapeutics presents additional data from its ICT-107 Phase I clinical trial

ImmunoCellular Therapeutics, Ltd., a biotechnology company that is focused on the development of novel immune-based cancer therapies, today announced additional data from its Phase I clinical trial evaluating ICT-107, the Company’s dendritic-cell based cancer vaccine product candidate for the treatment of glioblastoma multiforme (GBM).

27 Oct 2009

Champions Biotechnology obtains global rights to Tel Aviv University's TAR-1 compound

Champions Biotechnology, Inc., an oncology drug development company with a predictive preclinical platform aimed at accelerating the development and enhancing the value of oncology drugs, has established an exclusive licensing agreement with Ramot at Tel Aviv University Ltd., Tel Aviv University's wholly owned technology transfer company.

27 Oct 2009

Positive results from Logical Therapeutics' Phase I/II LT-NS001 clinical study

Logical Therapeutics, Inc., a Waltham, MA-based biopharmaceutical company announced today the positive results of a Phase I/II clinical trial evaluating the gastrointestinal (GI) safety of its investigational drug LT-NS001, the first of a new class of bio-activated prodrugs being developed for the chronic treatment of arthritic conditions.

27 Oct 2009

New Trace Express Viewer software from CDC Software

CDC Software Corporation, a global provider of enterprise software applications and services, today announced the availability of Trace Express Viewer, a new solution for its Ross ERP Lot Trace application that enables easier use, faster access and immediate forward and backward trace functionality to identify suspect materials and assist in the disposition of finished goods in the event of a product recall - key functionalities for product safety and compliance.

27 Oct 2009

Helicos Biosciences reports operational highlights for the third quarter of 2009

Helicos BioSciences Corporation announced today its operational, technical and scientific highlights for the quarter ended September 30, 2009.

27 Oct 2009

Life Technologies reports third quarter 2009 results; non-GAAP and organic revenues increase by 3% and 5%

Life Technologies Corporation (NASDAQ:LIFE) today announced results for its third quarter ended September 30, 2009. Non-GAAP revenue for the third quarter was $805 million, an increase of 3 percent over third quarter revenue of $784 million in 2008, as if Invitrogen and Applied Biosystems had been combined.

From Danaher 27 Oct 2009

PolyMedix completes second successful clinical study of PMX-60056

PolyMedix, Inc. (http://polymedix.com), an emerging biotechnology company developing new therapeutic drug products to treat infectious diseases and acute cardiovascular disorders, has completed a second successful clinical study of its anticoagulant reversing agent, PMX-60056.

27 Oct 2009

Compugen announces financial results for the third quarter ended September 30, 2009

Compugen Ltd. today reported financial results for the third quarter ended September 30, 2009.

27 Oct 2009

LX211 may become the first approved oral treatment for modifying the course of uveitis

An experimental drug, LX211 (LUVENIQ-; oral voclosporin), may become the first approved oral treatment capable of modifying the course of uveitis, a group of serious eye conditions inevitably associated with either severe vision loss or substantial morbidity from steroid use.

27 Oct 2009

Issuance of patents for Idera Pharmaceuticals' TLR-targeted compounds announced

Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced the issuance of patents covering its novel Toll-like Receptor (TLR) - targeted compounds. The Company’s TLR-targeted compounds are based on synthetic DNA and RNA, which it refers to as immune modulatory oligonucleotides, or IMO®.

27 Oct 2009

eBioscience acquires privately held immunoassay technology pioneer Bender MedSystems

eBioscience Corporation today announced that it has acquired privately held immunoassay technology pioneer Bender MedSystems GmbH in an all cash transaction. The acquisition will provide eBioscience with over 1,000 high profile immunology and oncology products including the Instant ELISA® and FlowCytomix(TM) brands that target the life sciences and diagnostics markets.

27 Oct 2009

Syngenta Ventures makes equity investment in Metabolon

Syngenta Ventures announced today that it has made an equity investment in Metabolon, a privately-held U.S. biotechnology company focused on the use of metabolomics in research and diagnostics.

27 Oct 2009

Arzerra drug approved by FDA for treating chronic lymphocytic leukemia

The U.S. Food and Drug Administration today approved Arzerra (ofatumumab) for patients with chronic lymphocytic leukemia (CLL), a slowly progressing cancer of the blood and bone marrow.

27 Oct 2009

Champions Biotechnology expands collaboration to accelerate oncology drug development

Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a company with a predictive preclinical platform aimed at accelerating the development and enhancing the value of oncology drugs, has established an agreement with Ortho Biotech Oncology Research & Development, a Division of Janssen Pharmaceutica NV, for the evaluation of a novel preclinical oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.

27 Oct 2009

Wound Management Technologies signs distribution agreement with Biocure S.r.l. of Milan

Wound Management Technologies, Inc., through its subsidiary, Wound Care Innovations, announced today that it has reached an agreement with Biocure S.r.l. of Milan, Italy for the distribution of WNDM's patented molecular form of activated collagen, CellerateRx®.

26 Oct 2009

Cephalon, BDC sign option agreement

Cephalon, Inc. and BioAssets Development Corporation (BDC), a privately held biopharmaceutical company, today announced that the companies have signed an agreement that will provide Cephalon with an option to acquire BDC.

26 Oct 2009

ImmunoCellular Therapeutics to present Phase I clinical trial data of ICT-107 vaccine in New Orleans

ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a clinical-stage biotechnology company that is developing immune-based therapies for the treatment of brain and other cancers, today announced that it will be presenting today, at the Annual Meeting of the Congress of Neurological Surgeons in New Orleans, Louisiana at 3:15pm central time, data from its Phase I clinical trial investigating the role that its ICT-107 vaccine may play in increasing patient survival and inhibiting tumor progression in patients with glioblastoma, the most common and most aggressive type of primary brain tumor.

26 Oct 2009

UCSF presents update of Phase 2 clinical trial of Oncophage cancer vaccine at SNO 2009

Antigenics today announced that the Brain Tumor Research Center at the University of California, San Francisco (UCSF), has presented an update on a Phase 2 clinical trial of Oncophage (vitespen) for recurrent high grade glioma (brain cancer) at the 2009 Joint Meeting of SNO (Society for Neuro-Oncology) and AANS/CNS Section on Tumors 2009 in New Orleans, LA.

26 Oct 2009

Biotechnology News and Research

Aquatrove Biosciences announces positive results from Conceive Plus study

Alkermes commences ALKS 37 phase 1 clinical trial for the treatment of opioid-induced constipation

ImmunoCellular Therapeutics presents additional data from its ICT-107 Phase I clinical trial

Champions Biotechnology obtains global rights to Tel Aviv University's TAR-1 compound

Positive results from Logical Therapeutics' Phase I/II LT-NS001 clinical study

New Trace Express Viewer software from CDC Software

Helicos Biosciences reports operational highlights for the third quarter of 2009

Life Technologies reports third quarter 2009 results; non-GAAP and organic revenues increase by 3% and 5%

PolyMedix completes second successful clinical study of PMX-60056

Compugen announces financial results for the third quarter ended September 30, 2009

LX211 may become the first approved oral treatment for modifying the course of uveitis

Issuance of patents for Idera Pharmaceuticals' TLR-targeted compounds announced

eBioscience acquires privately held immunoassay technology pioneer Bender MedSystems

Syngenta Ventures makes equity investment in Metabolon

Arzerra drug approved by FDA for treating chronic lymphocytic leukemia

Champions Biotechnology expands collaboration to accelerate oncology drug development

Wound Management Technologies signs distribution agreement with Biocure S.r.l. of Milan

Cephalon, BDC sign option agreement

ImmunoCellular Therapeutics to present Phase I clinical trial data of ICT-107 vaccine in New Orleans

UCSF presents update of Phase 2 clinical trial of Oncophage cancer vaccine at SNO 2009

Biotechnology eBook

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News